about
Unmet Needs in LDL-C Lowering: When Statins Won't Do!Role of Nutraceuticals in Hypolipidemic TherapyLDL cholesterol, statins and PCSK 9 inhibitorsNew developments in atherosclerosis: clinical potential of PCSK9 inhibitionPCSK9 inhibition: the way forward in the treatment of dyslipidemiaGenome-wide association studies of late-onset cardiovascular diseaseThe year in cardiology 2015: preventionCurrent and Emerging Uses of Statins in Clinical Therapeutics: A ReviewPCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the futurePCSK9 Inhibition With Monoclonal Antibodies: Modern Management of HypercholesterolemiaThe Genetics of Stress-Related Disorders: PTSD, Depression, and Anxiety DisordersFrom PK/PD to QSP: Understanding the Dynamic Effect of Cholesterol-Lowering Drugs on Atherosclerosis Progression and Stratified Medicine.PCSK9 and Atherosclerosis - Lipids and Beyond.Efficacy and safety of proprotein convertase subtilisin/kexin type 9 monoclonal antibody in adults with familial hypercholesterolemiaPCSK9 antibodies for the treatment of hypercholesterolemiaImpact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levelsVision from next generation sequencing: multi-dimensional genome-wide analysis for producing gene regulatory networks underlying retinal development, aging and diseaseContrasting genetic architectures in different mouse reference populations used for studying complex traits.Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trialsABCB1 C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins: a meta-analysisClinical and economic burden associated with cardiovascular events among patients with hyperlipidemia: a retrospective cohort studySelective stalling of human translation through small-molecule engagement of the ribosome nascent chain.How Do PCSK9 Inhibitors Stack Up to Statins for Low-Density Lipoprotein Cholesterol Control?A Phase I Randomized Study of a Specifically Engineered, pH-Sensitive PCSK9 Inhibitor RN317 (PF-05335810) in Hypercholesterolemic Subjects on Statin Therapy.Mechanisms and treatment of ischaemic stroke--insights from genetic associations.Psychiatric genetics and the future of personalized treatment.Ongoing challenges for pharmacotherapy for dyslipidemia.Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.Targeting PCSK9 for therapeutic gainsPharmacokinetics, Pharmacodynamics of Bococizumab, a monoclonal antibody to PCSK9, After Single Subcutaneous Injection at 3 Sites [NCT 02043301].The promise of proprotein convertase subtilisin/kexin 9 inhibitors for the treatment of familial hypercholesterolemia.Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention.Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology.PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab.Statins and their increased risk of inducing diabetes.An evaluation of alirocumab for the treatment of hypercholesterolemia.Genetic association studies in cardiovascular diseases: Do we have enough power?Human genetic insights into lipoproteins and risk of cardiometabolic disease.
P2860
Q26741705-F5809B53-51B2-4A6E-AD7E-5E49B34F4ACBQ26776125-25F5C9CC-7579-4A0A-ABDC-2B887BE1FDC6Q26782522-F7F4F9B3-E5D9-4169-9DA2-7AF49B0EF164Q26783407-35E944DE-E85A-4E71-AE6B-6F4F040A0BF1Q26784482-405EF534-D492-46EC-8DC1-509CEC3509AEQ27012711-EF5B3AB5-7E31-4B8C-9B09-01D0856DF283Q28072221-450D80A2-0A39-4A27-B50D-8E33BAA8029AQ28076346-2B70A3D0-448E-4B91-8A39-82DEB743F3C2Q28083595-22DC42AB-8D0F-45E3-BA26-B95DC37A09B2Q28275648-84E91760-D446-447D-9683-030146CACF03Q28396166-9E84EAA5-C2F1-4966-9347-D513AC421532Q33600357-8A823382-D805-49E9-98DA-4FE1497D7D37Q33675963-5688DA8E-EEE3-4B60-B453-1FD288A5F5BBQ33728343-DED7A905-4B59-41FC-99AA-070731EC0EFFQ34774969-5C690045-21BF-427F-9DBD-623527963E63Q35182551-82396BF4-0C84-4139-BF26-C0865DA0136FQ35470460-F667A45F-3CB3-4CBB-9FA0-3B107659AF40Q35664102-A5C1AAB2-3DE1-43C4-A13F-E5C0DC4BC30EQ35671077-B84D5003-4202-4C54-A504-F8FAED770446Q35799847-E751E974-B8F7-44EF-A1BF-C17242CF81B8Q35894735-CE6AA655-51AF-4D67-B4EC-16CC8A0B1BBAQ36316261-7EC69323-0299-4336-9C93-1FE80EA34092Q36385726-8EE961D1-E563-48D3-9562-6D6BCA95CA35Q37700671-43A11149-F586-4D17-A24D-20955118E295Q38263023-AA999AB0-5FB0-408A-8449-A9448BC244ABQ38269350-9CDA38C0-4794-407C-97FE-94F329FF4544Q38283386-E19E269A-3623-4AD4-9B63-389928AC83C6Q38325814-A76AEE4A-6B03-4917-9404-3CFF3FB5D90DQ38364882-9D1CCC0F-A221-4791-AA89-1510E4F50AB0Q38375213-434A9530-12B5-4FEE-A6EA-95A5A0820CB1Q38381808-A677A9F0-9284-4F85-8C0B-802326560F23Q38415231-60078B88-BAE2-4090-A864-56B319472EBFQ38546242-430E6A42-4EF3-44A2-B5CC-FD5DE8294AAFQ38570558-63C1427F-F842-4A5D-8C91-1C4C5C2C8215Q38586615-0CD32704-49E5-4698-8EE9-902DFCC6B285Q38596398-878E9BE4-5B15-4173-821F-C968399F421BQ38599323-A1B98792-D01B-4578-80A7-A663B376D0C7Q38632198-E39D51AF-595F-438E-B853-CCB978B81A5CQ38689422-02F37E66-D88F-4531-B370-EFAD066F9BE4Q38774074-3E1E4786-31B4-444F-976E-20EF80E7B761
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Lipid lowering with PCSK9 inhibitors.
@en
type
label
Lipid lowering with PCSK9 inhibitors.
@en
prefLabel
Lipid lowering with PCSK9 inhibitors.
@en
P2860
P356
P1476
Lipid lowering with PCSK9 inhibitors.
@en
P2093
Christie M Ballantyne
Razvan T Dadu
P2860
P304
P356
10.1038/NRCARDIO.2014.84
P407
P577
2014-06-24T00:00:00Z